I didn’t say the trials have been designed to satisfy the market - indeed the opposite - I said the with all the peer review there is no way IMU could design it other than in an appropriate manner. It is the Merino post I am concerned about as that infers that IMU is being clever for clever’s sake. Perhaps have another read.
Ann: PD1-Vaxx Presentation at ESMO Congress 2021 Annual Meeting, page-100
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |